Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
Results from the phase 3 FABULOUS trial demonstrated that the addition of apatinib to fuzuloparib significantly improved progression-free survival compared with fuzuloparib monotherapy or standard chemotherapy among patients with...
Results from the phase 3 FABULOUS trial demonstrated that the addition of apatinib to fuzuloparib significantly improved progression-free survival compared with fuzuloparib monotherapy or standard chemotherapy among patients with...
Sacituzumab govitecan prolongs progression-free survival vs standard chemotherapy among previously untreated patients with locally advanced, unresectable or metastatic triple-negative breast cancer unable to undergo PD-1/PD-L1 inhibition,...
Sacituzumab govitecan prolongs progression-free survival vs standard chemotherapy among previously untreated patients with locally advanced, unresectable or metastatic triple-negative breast cancer unable to undergo PD-1/PD-L1 inhibition,...
Results from the phase 2 AMALEE trial show that a 400 mg starting dose of ribociclib, combined with a nonsteroidal aromatase inhibitor, reduced dose-dependent adverse events while maintaining efficacy vs the standard dose in HR-positive,...
Results from the phase 2 AMALEE trial show that a 400 mg starting dose of ribociclib, combined with a nonsteroidal aromatase inhibitor, reduced dose-dependent adverse events while maintaining efficacy vs the standard dose in HR-positive,...
Primary analysis results from the phase 3 CULMINATE-2 trial show that adding culmerciclib to fulvestrant significantly improves outcomes among previously untreated patients with HR-positive, HER2-negative locally advanced or metastatic breast...
Primary analysis results from the phase 3 CULMINATE-2 trial show that adding culmerciclib to fulvestrant significantly improves outcomes among previously untreated patients with HR-positive, HER2-negative locally advanced or metastatic breast...
Results from the phase 3 ASCENT-03 trial show that sacituzumab govitecan significantly improved efficacy and safety compared with standard chemotherapy among previously untreated patients with metastatic triple-negative breast cancer unable...
Results from the phase 3 ASCENT-03 trial show that sacituzumab govitecan significantly improved efficacy and safety compared with standard chemotherapy among previously untreated patients with metastatic triple-negative breast cancer unable...
According to results from the BEGONIA study, first-line datopotamab deruxtecan plus durvalumab demonstrated clinical promise among patients with advanced or metastatic triple-negative breast cancer.
According to results from the BEGONIA study, first-line datopotamab deruxtecan plus durvalumab demonstrated clinical promise among patients with advanced or metastatic triple-negative breast cancer.
Extended follow-up results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment continued to prolong survival among patients with HR-positive, HER2-negative early breast...
Extended follow-up results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment continued to prolong survival among patients with HR-positive, HER2-negative early breast...
A retrospective study found a positive correlation between MYB gene abnormalities and HER2 status among patients with mammary adenoid cystic carcinoma.
A retrospective study found a positive correlation between MYB gene abnormalities and HER2 status among patients with mammary adenoid cystic carcinoma.
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
Do you know the clinical impact of trastuzumab deruxtecan and sacituzumab govitecan across the HER2-negative subgroups of patients with HR-positive, HER2-negative metastatic breast cancer? Test your knowledge with our quick quiz!
Do you know the clinical impact of trastuzumab deruxtecan and sacituzumab govitecan across the HER2-negative subgroups of patients with HR-positive, HER2-negative metastatic breast cancer? Test your knowledge with our quick quiz!
Do you know what the intracranial activity of trastuzumab deruxtecan was among patients with HER2-low metastatic breast cancer with active brain metastases? Test your knowledge with our quiz!
Do you know what the intracranial activity of trastuzumab deruxtecan was among patients with HER2-low metastatic breast cancer with active brain metastases? Test your knowledge with our quiz!
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
